Enanta Pharmaceuticals, Inc. (ENTA) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2025-11-19
Business type: Asset play
How it makes money
It earns royalties from AbbVie on HCV drug sales, relying on the commercial success of partner-led product distribution.
The company functions as an R&D engine, discovering antiviral compounds which it then out-licenses. Its primary source of revenue is a royalty stream from AbbVie, which manufactures and markets the finished combination treatments.
What protects it: the moat
It relies on intellectual property and patent protection for its small molecule drug candidates, though it asserts these protections rather than proving them.
The company claims that its drug discovery platform and specific inhibitors create a competitive advantage, but this is a management claim that must be tested by the successful defense of its patents in court.
What growth costs
It must heavily reinvest capital into clinical trials and R&D to survive, as royalty income is insufficient to cover development expenses.
Growth costs consist almost entirely of research and development, including preclinical manufacturing and clinical testing. The company explicitly states that these expenditures will exceed its current royalty revenues.
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.